LTR Pharma has been featured in the Stockhead article by respected biotech journalist Tim Boreham titled “The rise and rise of LTR Pharma.”
The article highlights the market opportunity for new treatments for Erectile Dysfunction, and LTR Pharma’s strategic path to market in Australia.
Here’s an excerpt:
“The value of the erectile dysfunction market is estimated at US$4.52 billion, with the US accounting for 30% despite having less than 10% of the sufferers.
The market is expected to grow to US$6 billion by 2028, despite what Rodne describes as a complete lack of erectile dysfunction treatment innovation.”